Company profile: XORTX Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for progressive kidney disease: XRx-008 for ADPKD to reduce cyst growth and improve kidney function; XRx-101 to lower uric acid for acute kidney injury and issues tied to serious viral infections, including COVID-19; and XRx-225, a pre-clinical treatment for Type 2 Diabetic Nephropathy targeting chronic kidney failure and end-stage kidney disease.
Products and services
- XRx-101: A formulation-based therapy that lowers uric acid to treat acute kidney injury and health issues associated with serious viral infections, including COVID-19
- XRx-008: A targeted therapy engineered to reduce kidney cyst growth and improve kidney function in progressive autosomal dominant polycystic kidney disease (ADPKD)
- XRx-225: A pre-clinical stage treatment targeting Type 2 Diabetic Nephropathy (T2DN) to address chronic kidney failure and end-stage kidney disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to XORTX Therapeutics
Design Therapeutics
HQ: United States
Website
- Description: Provider of GeneTAC small-molecule therapies that modulate gene expression to treat genetic diseases caused by nucleotide repeat expansions. Programs include Friedreich ataxia (DT-216, DT-216P2 to restore FXN), Fuchs endothelial corneal dystrophy (DT-168 eye drop), Huntington's disease (reduce mutant HTT), myotonic dystrophy DM1, and research for additional genetic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Design Therapeutics company profile →
Modus Therapeutics
HQ: Sweden
Website
- Description: Provider of sevuparin-based therapeutics in development to treat Sickle Cell Disease, sepsis/septic shock, and severe malaria, and to address anemia in chronic kidney disease and chronic inflammatory conditions; developing IV and subcutaneous formulations for hospital, ambulatory, and home care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modus Therapeutics company profile →
Cyclerion Therapeutics
HQ: United States
Website
- Description: Provider of soluble guanylate cyclase (sGC) pharmacology-based therapeutics, including praliciguat, an oral systemic sGC stimulator licensed to Akebia for rare kidney disease; olinciguat, an oral vascular sGC stimulator for cardiovascular diseases; and CNS-directed sGC stimulators zagociguat and CY3018 sold to Tisento, showing brain effects on blood flow, connectivity, cognition.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclerion Therapeutics company profile →
Spruce Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for rare endocrine diseases, including tildacerfont, a CRF1 receptor antagonist in late-stage clinical trials for classic congenital adrenal hyperplasia and potentially other conditions with elevated ACTH. Conducts CAHMELIA 203, a double-blind, placebo-controlled, dose-ranging study evaluating tildacerfont's efficacy and safety in adults with CAH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spruce Biosciences company profile →
Vidara Therapeutics
HQ: United States
Website
- Description: Provider of specialty pharmaceutical offerings, creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management; incorporated in 2003 and based in Dublin, Ireland.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vidara Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for XORTX Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to XORTX Therapeutics
2.2 - Growth funds investing in similar companies to XORTX Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for XORTX Therapeutics
4.2 - Public trading comparable groups for XORTX Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →